10-KPeriod: FY2007

AMGEN INC Annual Report, Year Ended Dec 31, 2007

Filed February 28, 2008For Securities:AMGN

Summary

Amgen Inc.'s 2007 10-K filing highlights a challenging year dominated by significant regulatory and reimbursement headwinds impacting its erythropoiesis-stimulating agent (ESA) products, Aranesp® and EPOGEN®. These challenges, stemming from observed adverse safety results in various studies and subsequent label updates and coverage restrictions by regulatory bodies like the FDA and CMS, led to a substantial reduction in ESA revenues, particularly Aranesp® sales in the U.S. supportive cancer care segment. In response, Amgen initiated a significant restructuring plan, involving staff reductions and operational rationalization, expecting charges of $775 million to $825 million. Despite these setbacks, Amgen reported notable accomplishments, including a successful defense of its intellectual property related to erythropoietin patents against Roche and continued advancement of its pipeline, with positive developments in its denosumab and Nplate™ programs. Strategic collaborations and acquisitions, such as those with Daiichi Sankyo and Takeda, as well as the acquisitions of Alantos and Ilypsa, underscore Amgen's commitment to expanding its R&D capabilities and product pipeline. The company's overall revenues saw a modest increase, driven by strong performance in ENBREL and Neulasta®, though this was substantially offset by the decline in Aranesp® sales. Investors should closely monitor the ongoing impact of regulatory changes, reimbursement policies, and pipeline progress for Amgen's future performance.

Financial Highlights

30 data points
Beta

Revenue

$14.77B

Net Income

$3.08B

20.8% Net Margin

EPS (Diluted)

$2.74

Cash & Equivalents

$2.02B

Free Cash Flow

$4.13B

Financial Statements
Beta
Revenue$14.77B
SG&A Expenses$3.36B
Operating Expenses$10.79B
Operating Income$3.98B
Interest Expense$496.00M
Net Income$3.08B
EPS (Basic)$2.76
EPS (Diluted)$2.74
Shares Outstanding (Basic)1.12B
Shares Outstanding (Diluted)1.12B

Key Highlights

  • 1Significant negative impact on ESA product sales (Aranesp®, EPOGEN®) due to safety concerns, regulatory label changes (FDA, EMEA), and restrictive reimbursement decisions (CMS, NKF).
  • 2Initiated a major restructuring plan, including staff reductions of 2,200-2,600 positions and operational rationalization, with estimated charges of $775-825 million.
  • 3Achieved a significant legal victory against Roche regarding erythropoietin patent infringement, reinforcing intellectual property.
  • 4Continued pipeline advancement with positive updates for denosumab (Phase 3 success) and Nplate™ (regulatory filings completed).
  • 5Diversified through strategic collaborations (Daiichi Sankyo, Takeda) and acquisitions (Alantos, Ilypsa) to bolster R&D and future product offerings.
  • 6Total revenues increased by 3% to $14.3 billion, driven by strong ENBREL and Neulasta® sales, but offset by a 12% decline in Aranesp® sales.
  • 7Cash, cash equivalents, and marketable securities stood at $7.2 billion at year-end, providing financial flexibility.

Frequently Asked Questions

Amgen faced significant challenges primarily related to its erythropoiesis-stimulating agent (ESA) products, Aranesp® and EPOGEN®. Adverse safety findings from clinical studies led to updated prescribing information, including boxed warnings, and restrictive reimbursement policies from the FDA and CMS. These factors materially impacted demand and sales, particularly for Aranesp® in the supportive cancer care segment.

In response to the negative impact on its ESA products and overall operations, Amgen announced a significant restructuring plan in August 2007. This plan involved reducing its global workforce by approximately 12-14% (2,200-2,600 positions) and rationalizing its manufacturing facilities to improve its cost structure. The company anticipated incurring substantial restructuring charges for these actions.

Despite the headwinds, Amgen achieved several key accomplishments. It successfully defended its erythropoietin patents in litigation against Roche, reinforcing its intellectual property. The company also made progress in its pipeline, with denosumab showing positive results in Phase 3 studies and Nplate™ completing regulatory filings. Strategic collaborations and acquisitions in diabetes, inflammatory diseases, and renal disorders also strengthened its future prospects.

Overall product sales increased by 3% to $14.3 billion. This growth was primarily driven by strong performance in ENBREL (up 12%) and Neulasta®/NEUPOGEN® (up 9%). However, this was substantially offset by a 12% decline in Aranesp® sales, which was significantly impacted by the regulatory and reimbursement challenges.